Harvard Bioscience Inc (HBIO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$8.02+0.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Broken: Primary pillar broken — Adjusted gross margin between 58% and 60% in fiscal year 2026: FY26 GM guidance 58.0% vs 58% target; Q2 actual 55.6%.
Harvard Bioscience aims for 2% to 4% revenue growth in 2026. It targets a gross margin near 58% to 60%. The company is consolidating manufacturing to cut costs. New management changes may improve execution.
The company is losing money and revenue fell in early 2026. Profit margins are under pressure. Management has been volatile and progress on goals is slow.
The market expects about 7% revenue growth. Our fair value is near $30, reflecting cautious optimism. We see risk in execution and margin delivery.
Breaks if: Gross margin falls below 58% in FY26
Breaks if: Progress stalls below 50% by mid-2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround opportunity. The company is currently loss-making but has shown strong recent financial performance and management is focused on growth and margin improvement.
The market seems to have priced in a low expectations gap, indicating that it views HBIO as relatively cheap compared to peers. However, there is a divergence in valuation, as it trades at a slight premium to its industry counterparts.
Management is on track to achieve its revenue and margin goals for 2026, with recent results showing positive growth. However, there is a high risk due to the company's volatile management history and a near-term miss probability of 38%.
The future performance of HBIO will depend on management's ability to maintain guidance and deliver on growth targets. Additionally, broader sector performance and economic indicators, such as job reports, will significantly impact the company's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company beat Q2 estimates and raised its revenue guidance. However, it also targeted a lower revenue growth range of 3% to 5%. This change challenges the previous growth outlook.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Strategic consolidation of manufacturing operations to improve efficiency and support long-term growth.
Breaks if: Revenue growth falls below 2% in FY26
In the next 1 to 3 years, HBIO's performance will be closely tied to its execution on growth and market conditions. Not investment advice.